NASDAQ · PODD
Healthcare · Medical - Devices
$139.24
Up+$0.43 (+0.31%)
Updated Sep 16, 2026, 1:37 PM
SID Score
4.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PODD closed at $139.24 after 20 trading sessions, down 5.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $137.59 | $140.28 | $136.16 | $139.24 | 1.5M |
| Sep 14, 2026 | $134.23 | $137.9801 | $131.61 | $137.80 | 2.34M |
| Sep 11, 2026 | $135.40 | $135.575 | $131.24 | $131.96 | 1.75M |
| Sep 10, 2026 | $136.74 | $138.66 | $134.11 | $134.68 | 1.87M |
| Sep 9, 2026 | $140.26 | $142.6919 | $137.25 | $137.92 | 2.06M |
| Sep 8, 2026 | $147.39 | $147.39 | $139.27 | $142.28 | 2.23M |
| Sep 4, 2026 | $149.32 | $150.56 | $145.42 | $147.48 | 1.06M |
| Sep 3, 2026 | $148.14 | $150.99 | $145.16 | $150.58 | 1.16M |
| Sep 2, 2026 | $148.00 | $151.50 | $147.21 | $148.14 | 1.11M |
| Sep 1, 2026 | $149.79 | $151.16 | $146.81 | $148.38 | 1.29M |
| Aug 31, 2026 | $142.93 | $149.68 | $142.005 | $148.66 | 6.64M |
| Aug 28, 2026 | $144.20 | $146.67 | $143.805 | $145.13 | 1.04M |
| Aug 27, 2026 | $142.96 | $144.60 | $140.98 | $143.41 | 1.34M |
| Aug 26, 2026 | $141.27 | $144.64 | $141.23 | $143.38 | 1.42M |
| Aug 25, 2026 | $145.28 | $146.095 | $141.78 | $143.05 | 1.93M |
| Aug 24, 2026 | $151.17 | $151.75 | $145.15 | $145.42 | 1.57M |
| Aug 21, 2026 | $146.87 | $150.20 | $145.035 | $148.16 | 903.61K |
| Aug 20, 2026 | $151.74 | $152.685 | $146.67 | $146.87 | 1.21M |
| Aug 19, 2026 | $148.00 | $155.17 | $147.955 | $151.51 | 1.31M |
| Aug 18, 2026 | $139.91 | $149.335 | $139.45 | $148.03 | 1.62M |
The latest Smart Investors Daily articles mentioning PODD.
PODD research
Company profile and research snapshot.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Leerink Partners | Market Perform | — |
| Aug 6, 2026 | Benchmark | Buy | — |
| Aug 6, 2026 | Bernstein | Outperform | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | TD Cowen | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...
Yahoo · Sep 8, 2026
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Yahoo · Sep 8, 2026
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Yahoo · Sep 4, 2026
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PODD.
